Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Aboukhatwa, Marwa ^a   Dosanjh, Laura ^a   Luo, Yuan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMYLOID PROTEIN; ANTIDEPRESSANT AGENT; CITALOPRAM; FLAVONOID; FLUOXETINE; FLUVOXAMINE; GINKGO BILOBA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; PAROXETINE; PLACEBO; REBOXETINE; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHOLINERGIC SYSTEM; COGNITION; COMORBIDITY; DEMENTIA; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; LEARNING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; MONOAMINERGIC SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNAPSE; URINARY TRACT DISEASE; WEIGHT GAIN; XEROSTOMIA;

EID: 77949450152     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-10     Document Type: Review

References (225)

1. New approaches to antidepressant drug discovery: beyond monoamines. O Berton EJ Nestler, Nature reviews. Neuroscience 2006 7 2 137 151 10.1038/nrn1846 16429123
2. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. ME Thase AA Nierenberg MB Keller J Panagides Group RPS, The Journal of clinical psychiatry 2001 62 10 782 788 11816867
3. Onset of action of antidepressants: results of different analyses. C Thompson, Human psychopharmacology 2002 17 Suppl 1 27 32 10.1002/hup.386 12404667
4. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? P Pacher V Kecskemeti, Current medicinal chemistry 2004 11 7 925 943 10.2174/0929867043455594 15078174
5. Cardiovascular effects of tricyclic antidepressants. AH Glassman, Annual Review of Medicine 1984 35 503 511 10.1146/annurev.me.35.020184.002443 6372670
6. Goodman & Gilman's the pharmacological basis of therapeutics. LS Goodman JG Hardman LE Limbird AG Gilman, New York: McGraw-Hill 10 2001 2148
7. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? P Pacher Z Ungvari PP Nanasi S Furst V Kecskemeti, Current medicinal chemistry 1999 6 6 469 480 10213794
8. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. EA Muth JT Haskins JA Moyer GE Husbands ST Nielsen EB Sigg, Biochemical pharmacology 1986 35 24 4493 4497 10.1016/0006-2952(86)90769-0 3790168
9. Preclinical pharmacology of milnacipran. M Briley JF Prost C Moret, International clinical psychopharmacology 1996 11 Suppl 4 9 14 8923122
10. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. MJ Detke Y Lu DJ Goldstein JR Hayes MA Demitrack, The Journal of clinical psychiatry 2002 63 4 308 315 12000204
11. Duloxetine Eli Lilly & Co. N Pitsikas, Current opinion in investigational drugs (London, England: 2000) 2000 1 1 116 121 11249587
12. Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man. G Cocchiara R Battaglia P Pevarello M Strolin Benedetti, European journal of drug metabolism and pharmacokinetics 1991 16 3 231 239 1814741
13. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. P Dostert MS Benedetti I Poggesi, European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 1997 7 Suppl 1 23 35 discussion S71-3. 10.1016/S0924-977X(97)00417-3 9169308
14. Serotonin reuptake inhibition: an update on current research strategies. D Spinks G Spinks, Current medicinal chemistry 2002 9 8 799 810 10.2174/0929867024606795 11966445
15. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. P Pacher Z Ungvari V Kecskemeti S Furst, Current medicinal chemistry 1998 5 5 381 390 9756980
16. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. B Rodriguez de la Torre J Dreher I Malevany M Bagli M Kolbinger H Omran B Luderitz ML Rao, Therapeutic drug monitoring 2001 23 4 435 440 10.1097/00007691-200108000-00019 11477329
17. Effects of SSRIs on sexual function: a critical review. RC Rosen RM Lane M Menza, Journal of clinical psychopharmacology 1999 19 1 67 85 10.1097/00004714-199902000-00013 9934946
18. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. PJ McGrath JW Stewart EV Nunes K Ocepek-Welikson JG Rabkin FM Quitkin DF Klein, The American Journal of Psychiatry 1993 150 1 118 123 8417553
19. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. JW Stewart E Tricamo PJ McGrath FM Quitkin, The American Journal of Psychiatry 1997 154 1 31 36 8988955
20. Mood disorders in the medically ill: scientific review and recommendations. DL Evans DS Charney L Lewis RN Golden JM Gorman KR Krishnan CB Nemeroff JD Bremner RM Carney JC Coyne MR Delong N Frasure-Smith AH Glassman PW Gold I Grant L Gwyther G Ironson RL Johnson AM Kanner WJ Katon PG Kaufmann FJ Keefe T Ketter TP Laughren J Leserman CG Lyketsos WM McDonald BS McEwen AH Miller D Musselman C O'Connor JM Petitto BG Pollock RG Robinson SP Roose J Rowland Y Sheline DS Sheps G Simon D Spiegel A Stunkard T Sunderland P Tibbits Jr WJ Valvo, Biological psychiatry 2005 58 3 175 189 10.1016/j.biopsych.2005.05. 001 16084838
21. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. RL Ownby E Crocco A Acevedo V John D Loewenstein, Archives of General Psychiatry 2006 63 5 530 538 10.1001/archpsyc.63.5.530 16651510
22. Neuropharmacology of depression in aging and age-related diseases. P Gareri P De Fazio G De Sarro, Ageing research reviews 2002 1 1 113 134 10.1016/S0047-6374(01)00370-0 12039452
23. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. DC Steffens BL Plassman MJ Helms KA Welsh-Bohmer AM Saunders JC Breitner, Biological psychiatry 1997 41 8 851 856 10.1016/S0006-3223(96)00247-8 9099411
24. Depressive syndromes in dementia. L Thorpe B Groulx Research CCfCC, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2001 28 Suppl 1 83 95 11237316
25. Antidepressive agents and memory. JM Danion, L'Encephale 1993 19 Spec No 2 417 422 8281908
26. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands. MI Geerlings RA Schoevers AT Beekman C Jonker DJ Deeg B Schmand HJ Ader LM Bouter W Van Tilburg, The British journal of psychiatry: the journal of mental science 2000 176 568 575 10.1192/bjp.176.6.568 10974964
27. Distinction between preclinical Alzheimer's disease and depression. PJ Visser FR Verhey RW Ponds A Kester J Jolles, Journal of the American Geriatrics Society 2000 48 5 479 484 10811539
28. Depressive symptomatology and incident cognitive decline in an elderly community sample. SS Bassuk LF Berkman D Wypij, Archives of General Psychiatry 1998 55 12 1073 1081 10.1001/archpsyc.55.12.1073 9862549
29. Major and minor depression in Alzheimer's disease: prevalence and impact. CG Lyketsos C Steele L Baker E Galik S Kopunek M Steinberg A Warren, The Journal of neuropsychiatry and clinical neurosciences 1997 9 4 556 561 9447496
30. Depression in Alzheimer's disease: heterogeneity and related issues. HB Lee CG Lyketsos, Biological psychiatry 2003 54 3 353 362 10.1016/S0006-3223(03) 00543-2 12893110
31. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. RC Green LA Cupples A Kurz S Auerbach R Go D Sadovnick R Duara WA Kukull H Chui T Edeki PA Griffith RP Friedland D Bachman L Farrer, Archives of Neurology 2003 60 5 753 759 10.1001/archneur.60.5.753 12756140
32. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. GS Zubenko WN Zubenko S McPherson E Spoor DB Marin MR Farlow GE Smith YE Geda JL Cummings RC Petersen T Sunderland, The American Journal of Psychiatry 2003 160 5 857 866 10.1176/appi.ajp.160.5. 857 12727688
33. The neuropathology of aminergic nuclei in Alzheimer's disease. RM Zweig CA Ross JC Hedreen C Steele JE Cardillo PJ Whitehouse MF Folstein DL Price, Annals of Neurology 1988 24 2 233 242 10.1002/ana.410240210 3178178
34. Major depression in primary dementia. Clinical and neuropathologic correlates. GS Zubenko J Moossy, Archives of Neurology 1988 45 11 1182 1186 3190497
35. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. RM Sapolsky, Archives of General Psychiatry 2000 57 10 925 935 10.1001/archpsyc.57.10.925 11015810
36. Depression in Alzheimer's disease: overview and treatment. CG Lyketsos J lin, Biological psychiatry 2002 52 3 243 252 10.1016/S0006-3223(02)01348-3 12182930
37. The stress and psychological morbidity of the Alzheimer patient caregiver. MT Gonzalez-Salvador C Arango CG Lyketsos AC Barba, International journal of geriatric psychiatry 1999 14 9 701 710 10.1002/(SICI)1099- 1166(199909)14:9<701::AID-GPS5>3.0.CO;2-# 10479740
38. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. L Teri, Alzheimer Disease and Associated Disorders 1997 11 Suppl 4 35 8 9339271
39. Family and Caregiver Issues in the Treatment of Patients With Alzheimer's Disease. RG Logsdon SM McCurry AL Moore L Teri, Seminars in clinical neuropsychiatry 1997 2 2 138 151 10320454
40. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. X Sun CC Chiu E Liebson NA Crivello L Wang J Claunch M Folstein I Rosenberg DM Mwamburi I Peter WQ Qiu, Alzheimer Dis Assoc Disord 2009 23 3 238 44 10.1097/WAD.0b013e31819cb3ac 19812466
41. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. WQ Qiu X Sun DJ Selkoe DM Mwamburi T Huang R Bhadela P Bergethon TM Scott P Summergrad L Wang I Rosenberg M Folstein, Int J Geriatr Psychiatry 2007 22 6 536 42 10.1002/gps.1710 17096467
42. Elevation in plasma Abeta42 in geriatric depression: a pilot study. N Pomara PM Doraiswamy LM Willoughby AE Roth BH Mulsant JJ Sidtis PD Mehta CF Reynolds III BG Pollock, Neurochem Res 2006 31 3 341 9 10.1007/s11064-005-9029-z 16583267
43. Diagnosis and treatment of depression comorbid with neurologic disorders. MA Raskind, The American Journal of Medicine 2008 121 11 Suppl 2 28 37 10.1016/j.amjmed.2008.09.011 18954590
44. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. CG Gottfries, Journal of neural transmission. Supplementum 1990 30 33 43 2202785
45. Functional neurochemistry of Alzheimer's disease. W Gsell G Jungkunz P Riederer, Current pharmaceutical design 2004 10 3 265 293 10.2174/ 1381612043386473 14754387
46. The molecular neurobiology of depression. V Krishnan EJ Nestler, Nature 2008 455 7215 894 902 10.1038/nature07455 18923511
47. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. CC Meltzer G Smith ST DeKosky BG Pollock CA Mathis RY Moore DJ Kupfer CF Reynolds III, Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 1998 18 6 407 430 9571651
48. Provisional diagnostic criteria for depression of Alzheimer disease. JT Olin LS Schneider IR Katz BS Meyers GS Alexopoulos JC Breitner ML Bruce ED Caine JL Cummings DP Devanand KR Krishnan CG Lyketsos JM Lyness PV Rabins CF Reynolds III BW Rovner DC Steffens PN Tariot BD Lebowitz, The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 2002 10 2 125 128 11925273
49. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. BV Reifler L Teri M Raskind R Veith R Barnes E White P McLean, The American Journal of Psychiatry 1989 146 1 45 49 2643356
50. Adult neurogenesis: from precursors to network and physiology. DN Abrous M Koehl M Le Moal, Physiological Reviews 2005 85 2 523 569 10.1152/physrev. 00055.2003 15788705
51. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. SW Levison JE Goldman, Neuron 1993 10 2 201 212 10.1016/0896-6273(93)90311-E 8439409
52. Investigation of glial cells in semithin sections. 3. Transformation of subependymal cells into glial cells, as shown by radioautography after 3 H-thymidine injection into the lateral ventricle of the brain of young rats. JA Paterson A Privat EA Ling CP Leblond, The Journal of comparative neurology 1973 149 1 83 102 10.1002/cne.901490106 4573360
53. Adult neurogenesis and neural stem cells of the central nervous system in mammals. P Taupin FH Gage, Journal of neuroscience research 2002 69 6 745 749 10.1002/jnr.10378 12205667
54. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Y Tatebayashi MH Lee L Li K Iqbal I Grundke-Iqbal, Acta Neuropathologica 2003 105 3 225 232 12557008
55. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. L Verret JL Jankowsky GM Xu DR Borchelt C Rampon, The Journal of neuroscience: the official journal of the Society for Neuroscience 2007 27 25 6771 6780 17581964
56. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. NL Chevallier S Soriano DE Kang E Masliah G Hu EH Koo, The American journal of pathology 2005 167 1 151 159 15972961
57. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. H Dong B Goico M Martin CA Csernansky A Bertchume JG Csernansky, Neuroscience 2004 127 3 601 609 10.1016/j.neuroscience.2004.05.040 15283960
58. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. MH Donovan U Yazdani RD Norris D Games DC German AJ Eisch, The Journal of comparative neurology 2006 495 1 70 83 10.1002/cne.20840 16432899
59. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. NJ Haughey D Liu A Nath AC Borchard MP Mattson, Neuromolecular medicine 2002 1 2 125 135 10.1385/NMM:1:2:125 12025858
60. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. NJ Haughey A Nath SL Chan AC Borchard MS Rao MP Mattson, Journal of neurochemistry 2002 83 6 1509 1524 10.1046/j.1471-4159.2002.01267.x 12472904
61. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. PH Wen X Shao Z Shao PR Hof T Wisniewski K Kelley VL Friedrich Jr L Ho GM Pasinetti J Shioi NK Robakis GA Elder, Neurobiology of disease 2002 10 1 8 19 10.1006/nbdi.2002.0490 12079399
62. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. M Vythilingam E Vermetten GM Anderson D Luckenbaugh ER Anderson J Snow LH Staib DS Charney JD Bremner, Biological psychiatry 2004 56 2 101 112 10.1016/j.biopsych.2004.04.002 15231442
63. Ginkgolide B, a constituent of Ginkgo biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminals. SJ Wang HH Chen, European journal of pharmacology 2005 514 2-3 141 149 15910800
64. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. JL Warner-Schmidt RS Duman, Hippocampus 2006 16 3 239 249 10.1002/hipo.20156 16425236
65. Age-related changes in multiple neurotransmitter systems in the monkey brain. GL Wenk DJ Pierce RG Struble DL Price LC Cork, Neurobiology of aging 1989 10 1 11 19 10.1016/S0197-4580(89)80005-3 2569169
66. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. BJ Williams M Eriksdotter-Jonhagen AC Granholm, Progress in neurobiology 2006 80 3 114 128 10.1016/j.pneurobio.2006.09.001 17084014
67. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. S Oddo A Caccamo M Kitazawa BP Tseng FM LaFerla, Neurobiology of aging 2003 24 8 1063 1070 10.1016/j.neurobiolaging.2003.08.012 14643377
68. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. S Oddo A Caccamo JD Shepherd MP Murphy TE Golde R Kayed R Metherate MP Mattson Y Akbari FM LaFerla, Neuron 2003 39 3 409 421 10.1016/S0896-6273(03)00434-3 12895417
69. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. JJ Rodriguez VC Jones M Tabuchi SM Allan EM Knight FM LaFerla S Oddo A Verkhratsky, PloS one 2008 3 8 2935 10.1371/journal.pone.0002935 18698410
70. Stem cell strategies for neuroreplacement therapy in Alzheimer's disease. K Sugaya CL Brannen, Medical hypotheses 2001 57 6 697 700 10.1054/mehy.2001. 1424 11918428
71. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. JE Malberg AJ Eisch EJ Nestler RS Duman, The Journal of neuroscience: the official journal of the Society for Neuroscience 2000 20 24 9104 9110 11124987
72. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. S Nakagawa JE Kim R Lee JE Malberg J Chen C Steffen YJ Zhang EJ Nestler RS Duman, The Journal of neuroscience: the official journal of the Society for Neuroscience 2002 22 9 3673 3682 11978843
73. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. M Sairanen G Lucas P Ernfors M Castren E Castren, The Journal of neuroscience: the official journal of the Society for Neuroscience 2005 25 5 1089 1094 15689544
74. Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus. S Nakagawa JE Kim R Lee J Chen T Fujioka J Malberg S Tsuji RS Duman, The Journal of neuroscience: the official journal of the Society for Neuroscience 2002 22 22 9868 9876 12427843
75. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. T Hajszan NJ MacLusky C Leranth, The European journal of neuroscience 2005 21 5 1299 1303 10.1111/j.1460-9568.2005.03968.x 15813939
76. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. SD Norrholm CC Ouimet, Synapse (New York, N.Y.) 2001 42 3 151 163 11746712
77. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. AM Magarinos A Deslandes BS McEwen, European journal of pharmacology 1999 371 2-3 113 122 10.1016/S0014-2999(99)00163-6 10357248
78. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. L Santarelli M Saxe C Gross A Surget F Battaglia S Dulawa N Weisstaub J Lee R Duman O Arancio C Belzung R Hen, Science (New York, N.Y.) 2003 301 5634 805 809 12907793
79. Assessing antidepressant activity in rodents: recent developments and future needs. JF Cryan A Markou I Lucki, Trends in pharmacological sciences 2002 23 5 238 245 10.1016/S0165-6147(02)02017-5 12008002
80. Stress, depression, and neuroplasticity: a convergence of mechanisms. C Pittenger RS Duman, Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2008 33 1 88 109 17851537
81. Forced swimming test in mice: a review of antidepressant activity. B Petit-Demouliere F Chenu M Bourin, Psychopharmacology (Berl) 2005 177 3 245 55 10.1007/s00213-004-2048-7 15609067
82. Effects of chronic fluoxetine in animal models of anxiety and depression. SC Dulawa KA Holick B Gundersen R Hen, Neuropsychopharmacology 2004 29 7 1321 30 10.1038/sj.npp.1300433 15085085
83. The neurobiology of memory changes in normal aging. CA Erickson CA Barnes, Exp Gerontol 2003 38 1-2 61 9 10.1016/S0531-5565(02)00160-2 12543262
84. Episodic spatial memory in adulthood. B Uttl P Graf, Psychol Aging 1993 8 2 257 73 10.1037/0882-7974.8.2.257 8323729
85. Age-related differences in an ecologically based study of route learning. SM Wilkniss MG Jones DL Korol PE Gold CA Manning, Psychol Aging 1997 12 2 372 5 10.1037/0882-7974.12.2.372 9189997
86. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. GW Small PV Rabins PP Barry NS Buckholtz ST DeKosky SH Ferris SI Finkel LP Gwyther ZS Khachaturian BD Lebowitz TD McRae JC Morris F Oakley LS Schneider JE Streim T Sunderland LA Teri LE Tune, JAMA: the journal of the American Medical Association 1997 278 16 1363 1371 10.1001/jama.278.16.1363 9343469
87. Neurobiological changes in the hippocampus during normative aging. JP Lister CA Barnes, Archives of Neurology 2009 66 7 829 833 10.1001/archneurol. 2009.125 19597084
88. Discovering endophenotypes for major depression. G Hasler WC Drevets HK Manji DS Charney, Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2004 29 10 1765 1781 15213704
89. Regional and cellular fractionation of working memory. PS Goldman-Rakic, Proceedings of the National Academy of Sciences of the United States of America 1996 93 24 13473 13480 10.1073/pnas.93.24.13473 8942959
90. Cognitive control and brain resources in major depression: an fMRI study using the n-back task. PO Harvey P Fossati JB Pochon R Levy G Lebastard S Lehericy JF Allilaire B Dubois, NeuroImage 2005 26 3 860 869 10.1016/j.neuroimage.2005.02.048 15955496
91. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. G Rajkowska G O'Dwyer Z Teleki CA Stockmeier JJ Miguel-Hidalgo, Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2007 32 2 471 482 17063153
92. Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. Y Levkovitz N Grisaru M Segal, Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2001 24 6 608 616 11331140
93. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. CA Stewart IC Reid, Psychopharmacology 2000 148 3 217 223 10.1007/s002130050045 10755734
94. Experience-specific functional modification of the dentate gyrus through adult neurogenesis: a critical period during an immature stage. A Tashiro H Makino FH Gage, The Journal of neuroscience: the official journal of the Society for Neuroscience 2007 27 12 3252 3259 17376985
95. Synapse formation on neurons born in the adult hippocampus. N Toni EM Teng EA Bushong JB Aimone C Zhao A Consiglio H van Praag ME Martone MH Ellisman FH Gage, Nature neuroscience 2007 10 6 727 734 10.1038/nn1908 17486101
96. Chronic effects of trimipramine, an antidepressant, on hippocampal synaptic plasticity. G Massicotte J Bernard M Ohayon, Behavioral and neural biology 1993 59 2 100 106 10.1016/0163-1047(93)90808-U 8476377
97. Chronic imipramine treatment partially reverses the long-term changes of hippocampal synaptic plasticity in socially stressed rats. JC Von Frijtag A Kamal LG Reijmers LH Schrama R van den Bos BM Spruijt, Neuroscience letters 2001 309 3 153 156 10.1016/S0304-3940(01)02062-6 11514064
98. Enhanced long-term synaptic depression in an animal model of depression. R Holderbach K Clark JL Moreau J Bischofberger C Normann, Biological psychiatry 2007 62 1 92 100 10.1016/j.biopsych.2006.07.007 17141742
99. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. RM Vouimba C Munoz DM Diamond, Stress (Amsterdam, Netherlands) 2006 9 1 29 40 16753931
100. Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. C Rocher M Spedding C Munoz TM Jay, Cerebral cortex (New York, N.Y.: 1991) 2004 14 2 224 229 10.1093/cercor/bhg122 14704220
101. Comparison of behavioural effects of venlafaxine and imipramine in rats. E Nowakowska K Kus A Chodera, Arzneimittel-Forschung 2003 53 4 237 242 12785118
102. Behavioural effects of fluoxetine and tianeptine, two antidepressants with opposite action mechanisms, in rats. E Nowakowska K Kus A Chodera J Rybakowski, Arzneimittel-Forschung 2000 50 1 5 10 10683709
103. The influence of tobacco smoke and nicotine on antidepressant and memory-improving effects of venlafaxine. E Nowakowska K Kus E Florek A Czubak J Jodynis-Liebert, Human & experimental toxicology 2006 25 4 199 209 10.1191/0960327106ht611oa 16696296
104. Effects of tianeptine on spontaneous alternation, simple and concurrent spatial discrimination learning and on alcohol-induced alternation deficits in mice. R Jaffard E Mocaer JC Poignant J Micheau A Marighetto M Meunier D Beracochea, Behavioural pharmacology 1991 2 1 37 46 10.1097/00008877-199102000- 00006 11224046
105. Chronic treatment with the antidepressant amitriptyline prevents impairments in water maze learning in aging rats. JL Yau J Noble C Hibberd WB Rowe MJ Meaney RG Morris JR Seckl, The Journal of neuroscience: the official journal of the Society for Neuroscience 2002 22 4 1436 1442 11850470
106. Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. L Naudon M Hotte TM Jay, Psychopharmacology 2007 191 2 353 364 10.1007/s00213-006-0660-4 17219219
107. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. G Petracca A Teson E Chemerinski R Leiguarda SE Starkstein, The Journal of neuropsychiatry and clinical neurosciences 1996 8 3 270 275 8854297
108. Impaired spatial learning in the Morris water maze induced by serotonin reuptake inhibitors in rats. N Majlessi N Naghdi, Behav Pharmacol 2002 13 3 237 42 12122314
109. Modulation of NMDA receptors by glycine - introduction to some basic aspects and recent developments. CG Parsons W Danysz M Hesselink S Hartmann B Lorenz C Wollenburg G Quack, Amino acids 1998 14 1-3 207 216 10.1007/BF01345264 9871463
110. Glutamate in CNS disorders as a target for drug development: an update. CG Parsons W Danysz G Quack, Drug news & perspectives 1998 11 9 523 569 10.1358/dnp.1998.11.9.863689 15616669
111. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. RX Petrie IC Reid CA Stewart, Pharmacology & therapeutics 2000 87 1 11 25 10.1016/S0163-7258(00)00063-2 10924739
112. Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. CA Stewart IC Reid, Molecular psychiatry 2002 7 Suppl 1 15 22 10.1038/sj.mp.4001014 11986991
113. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. SE Hoey RJ Williams MS Perkinton, The Journal of neuroscience: the official journal of the Society for Neuroscience 2009 29 14 4442 4460 19357271
114. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. S Lesne C Ali C Gabriel N Croci ET MacKenzie CG Glabe M Plotkine C Marchand-Verrecchia D Vivien A Buisson, The Journal of neuroscience: the official journal of the Society for Neuroscience 2005 25 41 9367 9377 16221845
115. Synaptic plasticity and mood disorders. RS Duman, Molecular psychiatry 2002 7 Suppl 1 29 34 10.1038/sj.mp.4001016 11986993
116. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. PA Boyer P Skolnick LH Fossom, Journal of molecular neuroscience: MN 1998 10 3 219 233 10.1007/BF02761776 9770644
117. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. G Nowak Y Li IA Paul, European journal of pharmacology 1996 295 1 75 85 10.1016/0014-2999(95)00585-4 8925878
118. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. G Nowak R Trullas RT Layer P Skolnick IA Paul, The Journal of pharmacology and experimental therapeutics 1993 265 3 1380 1386 8099620
119. Chronic but not acute clomipramine alters the effect of NMDA receptor regulation of dopamine release in rat frontal cortex. M Pallotta J Segieth PS Whitton, Neuroscience letters 1999 262 3 187 190 10.1016/S0304-3940(99)00058-0 10218887
120. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. IA Paul RT Layer P Skolnick G Nowak, European journal of pharmacology 1993 247 3 305 311 10.1016/0922-4106(93)90199-J 7905831
121. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. JH Krystal G Sanacora H Blumberg A Anand DS Charney G Marek CN Epperson A Goddard GF Mason, Molecular psychiatry 2002 7 Suppl 1 71 80 10.1038/sj.mp.4001021 11986998
122. The involvement of glutamate in the pathophysiology of depression. A Palucha A Pilc, Drug news & perspectives 2005 18 4 262 268 10.1358/dnp.2005.18.4.908661 16034483
123. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. IA Paul G Nowak RT Layer P Popik P Skolnick, The Journal of pharmacology and experimental therapeutics 1994 269 1 95 102 8169857
124. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate- induced intracellular Ca2+ levels in neuronal culture. Z Cai PP McCaslin, European journal of pharmacology 1992 219 1 53 57 10.1016/0014-2999(92)90579-S 1397050
125. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. E Sernagor D Kuhn L Vyklicky Jr ML Mayer, Neuron 1989 2 3 1221 1227 10.1016/0896-6273(89)90306-1 2483111
126. (1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy. S Shuto K Yoshii A Matsuda, Japanese journal of pharmacology 2001 85 3 207 213 10.1254/jjp.85.207 11325012
127. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. BK Szasz A Mike R Karoly Z Gerevich P Illes ES Vizi JP Kiss, Biological psychiatry 2007 62 11 1303 1309 10.1016/j.biopsych. 2007.04.014 17659262
128. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). RT Layer P Popik T Olds P Skolnick, Pharmacology, biochemistry, and behavior 1995 52 3 621 627 10.1016/0091-3057(95)00155-P 8545484
129. MK-801 and enantiomers: potential antidepressants or false positives in classical screening models? E Panconi J Roux M Altenbaumer S Hampe RD Porsolt, Pharmacology, biochemistry, and behavior 1993 46 1 15 20 10.1016/0091-3057(93) 90310-P 8255906
130. Antidepressants for the new millennium. P Skolnick, European journal of pharmacology 1999 375 1-3 31 40 10.1016/S0014-2999(99)00330-1 10443562
131. Possible use of amantadine in depression. TJ Huber DE Dietrich HM Emrich, Pharmacopsychiatry 1999 32 2 47 55 10.1055/s-2007-979191 10333162
132. Antidepressant effects of ketamine in depressed patients. RM Berman A Cappiello A Anand DA Oren GR Heninger DS Charney JH Krystal, Biological psychiatry 2000 47 4 351 354 10.1016/S0006-3223(99)00230-9 10686270
133. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. E Engin D Treit CT Dickson, Neuroscience 2009 161 2 359 369 10.1016/j.neuroscience.2009.03.038 19321151
134. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. MP Mattson S Maudsley B Martin, Trends in neurosciences 2004 27 10 589 594 10.1016/j.tins.2004.08.001 15374669
135. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. L Tong PL Thornton R Balazs CW Cotman, The Journal of biological chemistry 2001 276 20 17301 17306 10.1074/jbc.M010450200 11278679
136. High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. DN Arvanitis A Ducatenzeiler JN Ou E Grodstein SD Andrews SR Tendulkar A Ribeiro-da-Silva M Szyf AC Cuello, Journal of neurochemistry 2007 103 1 216 228 17587310
137. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Y Bezchlibnyk LT Young, Canadian journal of psychiatry. Revue canadienne de psychiatrie 2002 47 2 135 148 11926075
138. Preclinical models: status of basic research in depression. EJ Nestler E Gould H Manji M Buncan RS Duman HK Greshenfeld R Hen S Koester I Lederhendler M Meaney T Robbins L Winsky S Zalcman, Biological psychiatry 2002 52 6 503 528 10.1016/S0006-3223(02)01405-1 12361666
139. Antiglucocorticoid drugs in the treatment of depression. VI Reus OM Wolkowitz, Expert opinion on investigational drugs 2001 10 10 1789 1796 10.1517/13543784.10.10.1789 11772285
140. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. PT Pang B Lu, Ageing research reviews 2004 3 4 407 430 10.1016/j.arr.2004.07.002 15541709
141. Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. N Egashira K Iwasaki A Takashima T Watanabe H Kawabe T Matsuda K Mishima S Chidori R Nishimura M Fujiwara, Brain research 2005 1059 1 7 12 10.1016/j.brainres.2005. 08.004 16182262
142. Autosomal dominant dementia with widespread neurofibrillary tangles. LA Reed TJ Grabowski ML Schmidt JC Morris A Goate A Solodkin GW Van Hoesen RL Schelper CJ Talbot MA Wragg JQ Trojanowski, Annals of Neurology 1997 42 4 564 572 10.1002/ana.410420406 9382467
143. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. AJ Nazarali GP Reynolds, Cellular and molecular neurobiology 1992 12 6 581 587 10.1007/BF00711237 1283363
144. Neurotrophins and depression. CA Altar, Trends in pharmacological sciences 1999 20 2 59 61 10.1016/S0165-6147(99)01309-7 10101965
145. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. F Karege G Perret G Bondolfi M Schwald G Bertschy JM Aubry, Psychiatry research 2002 109 2 143 148 10.1016/S0165-1781(02)00005-7 11927139
146. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. VA Vaidya GJ Marek GK Aghajanian RS Duman, The Journal of neuroscience: the official journal of the Society for Neuroscience 1997 17 8 2785 2795 9092600
147. Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. C Brandoli A Sanna MA De Bernardi P Follesa G Brooker I Mocchetti, The Journal of neuroscience: the official journal of the Society for Neuroscience 1998 18 19 7953 7961 9742162
148. Clinical relevance of the neurotrophins and their receptors. SJ Allen D Dawbarn, Clinical science (London, England: 1979) 2006 110 2 175 191 16411894
149. Neurotrophins, synaptic plasticity and dementia. O Arancio MV Chao, Current opinion in neurobiology 2007 17 3 325 330 10.1016/j.conb.2007.03.013 17419049
150. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. C Matrone A Di Luzio G Meli S D'Aguanno C Severini MT Ciotti A Cattaneo P Calissano, Journal of Alzheimer's disease: JAD 2008 13 1 81 96 18334760
151. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. C Matrone MT Ciotti D Mercanti R Marolda P Calissano, Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 13139 13144 10.1073/pnas.0806133105 18728191
152. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. AH Nagahara DA Merrill G Coppola S Tsukada BE Schroeder GM Shaked L Wang A Blesch A Kim JM Conner E Rockenstein MV Chao EH Koo D Geschwind E Masliah AA Chiba MH Tuszynski, Nature medicine 2009 15 3 331 337 10.1038/nm.1912 19198615
153. Nerve growth factor promotes survival of new neurons in the adult hippocampus. H Frielingsdorf DR Simpson LJ Thal DP Pizzo, Neurobiology of disease 2007 26 1 47 55 10.1016/j.nbd.2006.11.015 17270453
154. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. MH Tuszynski L Thal M Pay DP Salmon HS U R Bakay P Patel A Blesch HL Vahlsing G Ho G Tong SG Potkin J Fallon L Hansen EJ Mufson JH Kordower C Gall J Conner, Nature medicine 2005 11 5 551 555 10.1038/nm1239 15852017
155. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. O Lazarov J Robinson YP Tang IS Hairston Z Korade-Mirnics VM Lee LB Hersh RM Sapolsky K Mirnics SS Sisodia, Cell 2005 120 5 701 713 10.1016/j.cell.2005.01.015 15766532
156. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. NV Patel MN Gordon KE Connor RA Good RW Engelman J Mason DG Morgan TE Morgan CE Finch, Neurobiology of aging 2005 26 7 995 1000 10.1016/j. neurobiolaging.2004.09.014 15748777
157. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3×TgAD mice. RL Nelson Z Guo VM Halagappa M Pearson AJ Gray Y Matsuoka M Brown B Martin T Iyun S Maudsley RF Clark MP Mattson, Experimental neurology 2007 205 1 166 176 10.1016/j.expneurol.2007.01.037 17368447
158. Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental disorders. A Russo-Neustadt, Seminars in clinical neuropsychiatry 2003 8 2 109 118 10.1053/scnp.2003.50014 12728410
159. Assay to screen for molecules that associate with Alzheimer's related beta-amyloid fibrils. P Inbar MR Bautista SA Takayama J Yang, Analytical Chemistry 2008 80 9 3502 3506 10.1021/ac702592f 18380488
160. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. JT Rogers JD Randall CM Cahill PS Eder X Huang H Gunshin L Leiter J McPhee SS Sarang T Utsuki NH Greig DK Lahiri RE Tanzi AI Bush T Giordano SR Gullans, The Journal of biological chemistry 2002 277 47 45518 45528 10.1074/jbc.M207435200 12198135
161. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. S Payton CM Cahill JD Randall SR Gullans JT Rogers, Journal of molecular neuroscience: MN 2003 20 3 267 275 10.1385/JMN:20:3:267 14501007
162. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. LJ Morse SM Payton GD Cuny JT Rogers, Journal of molecular neuroscience: MN 2004 24 1 129 136 10.1385/JMN:24:1:129 15314261
163. Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region. S Tucker M Ahl A Bush D Westaway X Huang JT Rogers, Current Alzheimer research 2005 2 2 249 254 10.2174/1567205053585855 15974925
164. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. S Tucker M Ahl HH Cho S Bandyopadhyay GD Cuny AI Bush LE Goldstein D Westaway X Huang JT Rogers, Current Alzheimer research 2006 3 3 221 227 10.2174/156720506777632835 16842099
165. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. M Pakaski A Bjelik M Hugyecz P Kasa Z Janka J Kalman, Neurochemistry international 2005 47 3 190 195 10.1016/j.neuint.2005.03.004 15955598
166. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. AA Arjona AM Pooler RK Lee RJ Wurtman, Brain research 2002 951 1 135 140 10.1016/S0006-8993(02)03153-0 12231467
167. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. JD Buxbaum M Oishi HI Chen R Pinkas-Kramarski EA Jaffe SE Gandy P Greengard, Proceedings of the National Academy of Sciences of the United States of America 1992 89 21 10075 10078 10.1073/pnas.89.21.10075 1359534
168. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. RM Nitsch BE Slack RJ Wurtman JH Growdon, Science (New York, N.Y.) 1992 258 5080 304 307 1411529
169. Mechanism of action of St John's wort in depression: what is known? V Butterweck, CNS drugs 2003 17 8 539 562 10.2165/00023210-200317080-00001 12775192
170. The antidepressant mechanism of Hypericum perforatum. T Mennini M Gobbi, Life Sciences 2004 75 9 1021 1027 10.1016/j.lfs.2004.04.005 15207650
171. St John's wort for the treatment of depression. RC Shelton, Lancet neurology 2002 1 5 275 10.1016/S1474-4422(02)00129-1 12849421
172. Hypericum perforatum, a source of neuroactive lead structures. L Verotta, Current topics in medicinal chemistry 2003 3 2 187 201 10.2174/1568026033392589 12570773
173. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. A Singer M Wonnemann WE Muller, The Journal of pharmacology and experimental therapeutics 1999 290 3 1363 1368 10454515
174. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. V Butterweck G Jurgenliemk A Nahrstedt H Winterhoff, Planta Medica 2000 66 1 3 6 10.1055/s-2000-11119 10705724
175. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. V Butterweck F Petereit H Winterhoff A Nahrstedt, Planta Medica 1998 64 4 291 294 10.1055/s-2006-957437 9619107
176. Neuroprotective effect of H. perforatum extracts on beta-amyloid-induced neurotoxicity. BA Silva AC Dias F Ferreres JO Malva CR Oliveira, Neurotoxicity research 2004 6 2 119 130 10.1007/BF03033214 15325964
177. Influence of Hypericum perforatum extract and its single compounds on amyloid-beta mediated toxicity in microglial cells. B Kraus H Wolff J Heilmann EF Elstner, Life Sciences 2007 81 11 884 894 10.1016/j.lfs.2007.07.020 17725929
178. Hypericum extract and hyperforin: memory-enhancing properties in rodents. V Klusa S Germane M Noldner SS Chatterjee, Pharmacopsychiatry 2001 34 Suppl 1 61 9 10.1055/s-2001-15451 11518079
179. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. MC Dinamarca W Cerpa J Garrido JL Hancke NC Inestrosa, Molecular psychiatry 2006 11 11 1032 1048 10.1038/sj.mp.4001866 16880827
180. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. H Sakakibara K Ishida O Grundmann J Nakajima S Seo V Butterweck Y Minami S Saito Y Kawai Y Nakaya J Terao, Biological & pharmaceutical bulletin 2006 29 8 1767 1770 10.1248/bpb.29.1767 16880641
181. Preparation and definition of Ginkgo biloba extract. K Drieu, Presse medicale (Paris, France: 1983) 1986 15 31 1455 1457 2947081
182. Inhibition of hippocampal LTP by ginkgolide B is mediated by its blocking action on PAF rather than glycine receptors. EL Kondratskaya YV Pankratov UV Lalo SS Chatterjee OA Krishtal, Neurochemistry international 2004 44 3 171 177 10.1016/S0197-0186(03)00126-8 14568560
183. Antidepressant and antistress activity of GC-MS characterized lipophilic extracts of Ginkgo biloba leaves. SS Kalkunte AP Singh FC Chaves TJ Gianfagna VS Pundir AK Jaiswal N Vorsa S Sharma, Phytotherapy Research: PTR 2007 21 11 1061 1065 10.1002/ptr.2212 17639553
184. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. FV DeFeudis K Drieu, Current Drug Targets 2000 1 1 25 58 10.2174/1389450003349380 11475535
185. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. DO Kennedy AB Scholey KA Wesnes, Psychopharmacology 2000 151 4 416 423 10.1007/s002130000501 11026748
186. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. PL Le Bars MM Katz N Berman TM Itil AM Freedman AF Schatzberg, JAMA: the journal of the American Medical Association 1997 278 16 1327 1332 10.1001/jama.278.16.1327 9343463
187. Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. J Polich R Gloria, Human psychopharmacology 2001 16 5 409 416 10.1002/hup.308 12404561
188. The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. F Tang S Nag SY Shiu SF Pang, Life Sciences 2002 71 22 2625 2631 10.1016/S0024-3205(02)02105-7 12354581
189. The effects of Ginkgo biloba extract (LI 1370) supplementation and discontinuation on activities of daily living and mood in free living older volunteers. L Trick J Boyle I Hindmarch, Phytotherapy Research: PTR 2004 18 7 531 537 10.1002/ptr.1479 15305311
190. Ginkgo biloba for prevention of dementia: a randomized controlled trial. ST DeKosky JD Williamson AL Fitzpatrick RA Kronmal DG Ives JA Saxton OL Lopez G Burke MC Carlson LP Fried LH Kuller JA Robbins RP Tracy NF Woolard L Dunn BE Snitz RL Nahin CD Furberg GEoMGS Investigators, JAMA: the journal of the American Medical Association 2008 300 19 2253 2262 10.1001/jama.2008.683 19017911
191. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. ZX Yao Z Han K Drieu V Papadopoulos, The Journal of nutritional biochemistry 2004 15 12 749 756 10.1016/j.jnutbio.2004. 06.008 15607648
192. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Y Luo JV Smith V Paramasivam A Burdick KJ Curry JP Buford I Khan WJ Netzer H Xu P Butko, Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12197 12202 10.1073/pnas.182425199 12213959
193. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. S Bastianetto C Ramassamy S Dore Y Christen J Poirier R Quirion, The European journal of neuroscience 2000 12 6 1882 1890 10.1046/j.1460-9568.2000.00069.x 10886329
194. Restoration of impaired phosphorylation of cyclic AMP response element-binding protein (CREB) by EGb 761 and its constituents in Abeta-expressing neuroblastoma cells. Y Xu C Cui C Pang Y Christen Y Luo, The European journal of neuroscience 2007 26 10 2931 2939 10.1111/j.1460-9568.2007. 05905.x 18001288
195. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. F Tchantchou Y Xu Y Wu Y Christen Y Luo, The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2007 21 10 2400 2408 17356006
196. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. O Benavente-Garcia J Castillo, Journal of Agricultural and Food Chemistry 2008 56 15 6185 6205 10.1021/jf8006568 18593176
197. Rat electropharmacograms of the flavonoids rutin and quercetin in comparison to those of moclobemide and clinically used reference drugs suggest antidepressive and/or neuroprotective action. W Dimpfel, Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2009 16 4 287 294 19303757
198. Antidepressant-like effects of a cocoa polyphenolic extract in Wistar-Unilever rats. M Messaoudi JF Bisson A Nejdi P Rozan H Javelot, Nutritional Neuroscience 2008 11 6 269 276 10.1179/147683008X344165 19000380
199. Hypericum grandifolium Choisy: a species native to Macaronesian Region with antidepressant effect. CC Sanchez-Mateo CX Bonkanka RM Rabanal, Journal of ethnopharmacology 2009 121 2 297 303 10.1016/j.jep.2008.10.031 19041704
200. Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta(1-42) oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Q Li HF Zhao ZF Zhang ZG Liu XR Pei JB Wang Y Li, Neuroscience 2009
201. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. K Matsuzaki T Yamakuni M Hashimoto AM Haque O Shido Y Mimaki Y Sashida Y Ohizumi, Neuroscience letters 2006 400 3 230 234 10.1016/j.neulet.2006.02.077 16581185
202. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Y Hou MA Aboukhatwa DL Lei K Manaye I Khan Y Luo, Neuropharmacology 2009 19917299
203. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. AL Nyth CG Gottfries K Lyby L Smedegaard-Andersen J Gylding-Sabroe M Kristensen HE Refsum E Ofsti S Eriksson S Syversen, Acta Psychiatrica Scandinavica 1992 86 2 138 145 10.1111/j.1600-0447.1992.tb03242.x 1529737
204. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. C Magai G Kennedy CI Cohen D Gomberg, The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 2000 8 1 66 74 10648297
205. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. CG Lyketsos JM Sheppard CD Steele S Kopunek M Steinberg AS Baker J Brandt PV Rabins, The American Journal of Psychiatry 2000 157 10 1686 1689 10.1176/appi.ajp.157.10. 1686 11007727
206. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. S Thompson N Herrmann MJ Rapoport KL Lanctot, Canadian journal of psychiatry. Revue canadienne de psychiatrie 2007 52 4 248 255 17500306
207. Monoamine neurons in aging and Alzheimer's disease. AM Palmer ST DeKosky, Journal of neural transmission. General section 1993 91 2-3 135 159 10.1007/BF01245229 8099796
208. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. MS Mega DM Masterman SM O'Connor TR Barclay JL Cummings, Arch Neurol 1999 56 11 1388 93 10.1001/archneur.56.11.1388 10555660
209. Neurochemical basis for symptomatic treatment of Alzheimer's disease. PT Francis MJ Ramirez MK Lai, Neuropharmacology 2010 20156462
210. The cholinergic hypothesis of Alzheimer's disease: a review of progress. PT Francis AM Palmer M Snape GK Wilcock, J Neurol Neurosurg Psychiatry 1999 66 2 137 47 10.1136/jnnp.66.2.137 10071091
211. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. MW Decker JL McGaugh, Synapse (New York, N.Y.) 1991 7 2 151 168 1672782
212. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. M Rossor LL Iversen, British medical bulletin 1986 42 1 70 74 2869818
213. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. MK Lai SW Tsang PT Francis J Keene T Hope MM Esiri I Spence CP Chen, Neuroreport 2002 13 9 1175 1178 10.1097/00001756-200207020-00021 12151764
214. Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. M Riekkinen R Tolonen P Riekkinen Jr, Brain research 1994 649 1-2 174 180 10.1016/0006-8993(94)91061-8 7953629
215. Serotonin and human cognitive performance. JA Schmitt M Wingen JG Ramaekers EA Evers WJ Riedel, Current pharmaceutical design 2006 12 20 2473 2486 10.2174/138161206777698909 16842171
216. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. A Mowla M Mosavinasab H Haghshenas AB Haghighi, Journal of clinical psychopharmacology 2007 27 5 484 487 10.1097/jcp.0b013e31814b98c1 17873681
217. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. SI Finkel JE Mintzer M Dysken KR Krishnan T Burt T McRae, International journal of geriatric psychiatry 2004 19 1 9 18 10.1002/gps.998 14716694
218. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval. HJ Altman WS Stone SO Ogren, Behavioral and neural biology 1987 48 1 49 62 10.1016/S0163-1047(87)90574-7 3632552
219. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. EC Azmitia M Segal, The Journal of comparative neurology 1978 179 3 641 667 10.1002/cne.901790311 565370
220. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. JT Little A Broocks A Martin JL Hill LE Tune C Mack M Cantillon S Molchan DL Murphy T Sunderland, Psychopharmacology 1995 120 3 280 288 10.1007/BF02311175 8524975
221. Acetylcholine release in the hippocampus: regulation by monoaminergic afferents as assessed by in vivo microdialysis. OG Nilsson G Leanza A Bjorklund, Brain research 1992 584 1-2 132 140 10.1016/0006-8993(92)90886-E 1355389
222. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. GS Smith E Kramer Y Ma CR Hermann V Dhawan T Chaly D Eidelberg, Brain: a journal of neurology 2009 132 Pt 2 392 401 19153152
223. Near-total loss of 'learning' and 'memory' as a result of combined cholinergic and serotonergic blockade in the rat. CH Vanderwolf, Behavioural brain research 1987 23 1 43 57 10.1016/0166-4328(87)90241-5 2950902
224. Novel therapeutic approaches beyond the serotonin receptor. RS Duman, Biological psychiatry 1998 44 5 324 335 10.1016/S0006-3223(98)00031-6 9755354
225. Pharmacotherapy for Alzheimer's disease: progress and prospects. AM Palmer, Trends in pharmacological sciences 2002 23 9 426 433 10.1016/S0165-6147(02)02056-4 12237155